Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

MLA

Goldberg, Sarah B., et al. “Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 38, no. 34, Dec. 2020, pp. 4076–85. EBSCOhost, https://doi.org/10.1200/JCO.20.01149.

APA

Goldberg, S. B., Redman, M. W., Lilenbaum, R., Politi, K., Stinchcombe, T. E., Horn, L., Chen, E. H., Mashru, S. H., Gettinger, S. N., Melnick, M. A., Herbst, R. S., Baumgart, M. A., Miao, J., Moon, J., Kelly, K., & Gandara, D. R. (2020). Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 38(34), 4076–4085. https://doi.org/10.1200/JCO.20.01149

Chicago

Goldberg, Sarah B, Mary W Redman, Rogerio Lilenbaum, Katerina Politi, Thomas E Stinchcombe, Leora Horn, Everett H Chen, et al. 2020. “Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 38 (34): 4076–85. doi:10.1200/JCO.20.01149.